8-K filing — MIMEDX GROUP, INC. (MDXG)
Filed: 2026-10-16 AccNo: 0001213900-26-110041 Size: 205 KB Item 8.01: Other Events
Stocks · News reference
MiMedx, Sanara Receive U.S. Federal Trading Commission Second Request For Additional Information, Documentary Materials For Proposed Business Combination
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026
MiMedx Group, Inc. announced it will report Q3 2026 financial results on October 28, 2026, followed by a webcast and conference call at 4:30 p.m. ET. The company also announced a favorable federal court ruling vacating FDA determinations regarding AXIOFILL's regulatory classification as a biological product.
MiMedx Group Announces U.S. Court Issues Favorable Ruling In Co.'s Litigation Against FDA's Regulatory Classification Of AXIOFILL
MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that the U.S. District Court for the Northern District of Georgia issued a favorable ruling in the Company’s litigation